Small molecule · Agonist of stimulator of interferon genes protein (STING1) · developed by TAKEDA PHARMACEUTICAL CO
Dazostinag (TAK-676) is an agonist of the STING protein (TMEM173) that is given intravenously. It binds STING and activates the STING pathway in immune cells of the tumor microenvironment, driving pro-inflammatory cytokine and interferon production and a cytotoxic T-lymphocyte response. It is being studied in solid neoplasms.
Summary written with AI from the sources listed at the end of this page.
Solid Neoplasms
Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →